This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
by Zacks Equity Research
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
GSKPositive Net Change RAPTPositive Net Change ALGSNegative Net Change
biotechs
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
RHHBYPositive Net Change MRKNegative Net Change CGENPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
GSKPositive Net Change MRNAPositive Net Change RCKTNegative Net Change RNACNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
NERVNegative Net Change ARGXPositive Net Change ALXOPositive Net Change RNACNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna vaccines
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
by Zacks Equity Research
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
VRTXPositive Net Change RAPTPositive Net Change ALGSNegative Net Change ACRVNegative Net Change
biotechs
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
by Zacks Equity Research
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change ALGSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
REGNPositive Net Change SNYPositive Net Change NERVNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
by Zacks Equity Research
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.
RAPTPositive Net Change ALGSNegative Net Change ACRVNegative Net Change
biotechs
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change MDGLNegative Net Change
biotechs medical pharmaceuticals
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
CGENPositive Net Change XENEPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
by Zacks Equity Research
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
NVSPositive Net Change INCYPositive Net Change MESOPositive Net Change ALXOPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
4 Best-Performing Sector ETFs of June
by Sweta Killa
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
AMLPPositive Net Change BBPPositive Net Change MAGSPositive Net Change WGMIPositive Net Change
biotechs bitcoin etfs fang
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
by Zacks Equity Research
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
GSKPositive Net Change PFENegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
CGENPositive Net Change HRTXPositive Net Change RCKTNegative Net Change ARQTNegative Net Change
biotechs gene-therapy medical
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
by Zacks Equity Research
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
REGNPositive Net Change SNYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs pharmaceuticals
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
by Zacks Equity Research
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
CGENPositive Net Change APLSPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
CGENPositive Net Change PTCTPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
CDC Narrows Age Recommendation for Use of RSV Vaccine
by Zacks Equity Research
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
GSKPositive Net Change PFENegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
PFENegative Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs pharmaceuticals
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
by Zacks Equity Research
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
CGENPositive Net Change COGTPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
by Zacks Equity Research
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
SNYPositive Net Change BIIBPositive Net Change DNLIPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
MRKNegative Net Change CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
ALNYPositive Net Change ALIMPositive Net Change JAZZPositive Net Change SRPTPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals